Brief: Ampio Provides Update On Osteoarthritis Of The Knee (Oak) Program, Reiterates Compelling Data In Earlier Phase Iii Trials Of Ampion In Severe Oak
17/06/2021 14:17
June 17 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO PROVIDES UPDATE ON OSTEOARTHRITIS OF THE KNEE (OAK)
PROGRAM, REITERATES COMPELLING DATA IN EARLIER PHASE III TRIALS
OF AMPION IN SEVERE OAK
* AMPIO PHARMACEUTICALS INC - POOLED DATA FROM AP-003-C
PHASE III
CLINICAL TRIAL SHOW AN EVEN GREATER STATISTICAL SIGNIFICANCE
* AMPIO PHARMACEUTICALS INC - FDA HAS PROVIDED WRITTEN
CONFIRMATION THAT AP-003-A STUDY PROVIDES EVIDENCE OF
EFFECTIVENESS OF AMPION
Source text for Eikon: ID:nPn6kxt7sa
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank